Pd52-09 Effect of the Glucagon Like Peptide 1 Receptor Agonist, Semaglutide in Obese Men With Mild to Moderate Erectile Dysfunction: A Prospective Observational Study

You have accessJournal of UrologySexual Function/Dysfunction: Medical, Hormonal & Non-surgical Therapy II (PD52)1 May 2024PD52-09 EFFECT OF THE GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST, SEMAGLUTIDE IN OBESE MEN WITH MILD TO MODERATE ERECTILE DYSFUNCTION: A PROSPECTIVE OBSERVATIONAL STUDY Edoardo Pozzi, Aymara Evans, Nicholas Deebel, and Ranjith Ramasamy Edoardo PozziEdoardo Pozzi , Aymara EvansAymara Evans , Nicholas DeebelNicholas Deebel , and Ranjith RamasamyRanjith Ramasamy View All Author Informationhttps://doi.org/10.1097/01.JU.0001009412.04863.1b.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Obesity is a prevalent health concern that notably impairs male sexual function through hormonal disruptions and other pathophysiological alterations. Hormonal imbalances are a central factor in how excess weight impairs erectile function. We aimed to conduct a prospective observational study in obese men with erectile dysfunction treated with the injectable Semaglutide to assess changes in erectile function. METHODS: Initial data from men with obesity (BMI >30) and mild to moderate erectile dysfunction (according to the International Index of Erectile Function - Erectile Function domain [IIEF-EF]) were enrolled in the study. Baseline serum hormones were dosed for every patient. Injectable Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, was prescribed as a subcutaneous injection at an initial dose of 0.25 mg once a week, followed by an escalation to 0.5 mg per week starting in the 4th week. Baseline assessments of erectile function (IIEF-EF), hormonal profiles, and metabolic parameters were conducted. Scheduled follow-up data collection is planned at the 3-month, 6-month, and 12-month intervals. Descriptive statistics were used to detail baseline patients' characteristics and will be used to detail changes over the follow-up time marks. RESULTS: Overall, the median (IQR) age of the recruited patients was 45 (38-52) years, and the median (IQR) BMI was 32.6 (30.4-37.67) kg/m2. Preliminary analysis at follow-up can indicate a modest improvement in the IIEF-EF scores among participants, suggesting a potential positive trend in erectile function with Semaglutide treatment. However, it is crucial to interpret these findings with caution due to the study's small sample size, emphasizing the need for continued observation and a larger participant cohort to draw more robust conclusions regarding the long-term effects of Semaglutide on erectile function in obese men. CONCLUSIONS: This ongoing prospective observational study provides a foundation for further research into the relationship between Semaglutide, obesity, and male sexual function. The findings may contribute to a better understanding of the potential benefits or concerns associated with Semaglutide use in this specific population, guiding future investigations and clinical interventions. Further follow-up and expansion of the participant cohort are essential for comprehensive data interpretation and generalizability of the study outcomes. Source of Funding: Supported by NIDDK grants R01 DK130991, UE5 DK137308, and Clinician Scientist Development Grant from American Cancer Society to Ranjith Ramasamy © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1075 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Edoardo Pozzi More articles by this author Aymara Evans More articles by this author Nicholas Deebel More articles by this author Ranjith Ramasamy More articles by this author Expand All Advertisement PDF downloadLoading ...